Figure 4.

In vivo biodistribution of Hybrid c(RGDm7)-LS. (a) In vivo whole-body imaging of subcutaneous A549 tumour-bearing nude mice injected intravenously with different DiR-labelled nanoformulations at 4 h with or without pre-block. (b) IVIS fluorescence image of tumours and main organs 4 h post-injection with or without pretreatment. (c, d) Quantification of the mean fluorescence signal intensities of major organs and tumours from model nude mice, respectively. Data were mean ± SD (n = 3, *p < 0.05, **p < 0.01, ***p < 0.001).